Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DO5H6K
|
|||
| Drug Name |
OT-101
|
|||
| Drug Type |
Antisense oligonucleotide
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 2/3 | [1] | |
| Merkel cell carcinoma [ICD-11: 2C34; ICD-10: C44] | Phase 2/3 | [1] | ||
| Pancreatic cancer [ICD-11: 2C10] | Phase 2/3 | [2] | ||
| Recurrent glioblastoma [ICD-11: 2A00.00; ICD-10: C71] | Phase 2/3 | [2], [3] | ||
| Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 2 | [4] | ||
| Company |
Mateon/Oncotelic
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | ClinicalTrials.gov (NCT04801017) A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects. U.S. National Institutes of Health. | |||
| REF 5 | Clinical pipeline report, company report or official report of Oncotelic. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.